Loading organizations...
Laigo Bio, based in Utrecht, Netherlands, is a biotechnology company developing SureTACs, a targeted protein degradation technology designed to remove disease-causing membrane proteins from cell surfaces. The platform redirects transmembrane E3 ligases for ubiquitination, endocytosis, and degradation, focusing on precision therapeutics for severe conditions, initially in oncology and neurological disorders. The company has secured a total of €17 million in funding, including an €11.5 million seed round. Key backers include Oncode Bridge Fund and ArgoBio, with support from the Oncode Institute. Laigo Bio is advancing its proprietary pipeline toward preclinical leads and aims for its first clinical studies in 2025. The organization was founded in 2024 by Madelon Maurice and Neill Moray Mackenzie. Its business model centers on biotech startup funded by seed investments from Oncode Bridge Fund, ArgoBio, and others to advance its proprietary pipeline toward Series A and clinical studies.
Laigo Bio has raised $649.4M across 2 funding rounds.
Laigo Bio has raised $649.4M in total across 2 funding rounds.
Laigo Bio has raised $649.4M in total across 2 funding rounds.
Laigo Bio's investors include Biovance Capital, Kurma Partners, Angelini Ventures, ArgoBio, Cancer Research Horizons, Curie Capital, Eurazeo, Oncode Oncology Bridge Fund, ROM Utrecht Region, Mariette van der Velden, Thierry Laugel, Lola Buono.
Laigo Bio has raised $649.4M across 2 funding rounds. Most recently, it raised $636.0M Seed Extension in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 23, 2026 | $636M Seed Plus | Biovance Capital, Kurma Partners | Angelini Ventures, ARGOBIO, Cancer Research Horizons, Curie Capital, Eurazeo, Oncode Oncology Bridge Fund, ROM Utrecht Region | Announced |
| Dec 4, 2025 | $13.4M Seed | Mariette VAN DER Velden, Thierry Laugel | Lola Buono, Neill Moray Mackenzie, Phil Masterson, Eurazeo, Emil POT, ROM Utrecht Region | Announced |
